• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

GLP-1 Patients Missed Over $10M in Potential Savings in a Single Quarter, Report Finds

by Jasmine Pennic 06/23/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– A new data analysis from DoseSpot, a leader in e-prescribing and healthcare technology solutions, found that 92 percent of GLP-1 prescriptions the company processed in Q1 2025 could have been filled at a lower price. This translates to a staggering $10.2M in missed savings for patients on these popular medications.

– The analysis of over 100,000 prescriptions highlights a significant gap in cost transparency and access to savings programs, contributing to the high cost of these drugs for millions of Americans.

A Widespread Problem with a Simple Solution

The analysis focused on 102,166 prescriptions for manufacturer brands like Mounjaro, Ozempic, and Zepbound. It evaluated whether each prescription was eligible for additional savings through different pharmacies or via manufacturer cost-saving programs.

The findings were clear: the vast majority of patients are overpaying. The potential savings would have come from three key areas:

  1. Giving patients transparent pharmacy pricing information.
  2. Letting patients choose their pharmacy or dispensing option.
  3. Utilizing manufacturer cost-savings programs.

The bulk of the potential savings—a massive $7M—would have come directly from manufacturer cost-savings programs, which many patients are simply unaware of.

The High Cost of Non-Adherence

With 1 in 8 American adults having reported using a GLP-1, and cost being the top reason why 33% of Americans don’t fill their prescriptions, these missed savings have a direct impact on medication adherence and health outcomes. Out-of-pocket drug spending is on the rise, increasing by 25% over the last five years to $98 billion in 2024.

GLP-1 medication adherence is particularly low, with just 46.3% of users still on the medication after 180 days. Savings programs are a critical component to improving adherence, not just for one-time use but on a recurring basis.

“Regardless of their insurance status, the vast majority of patients are still unaware of cost saving programs,” said Josh Weiner, CEO of DoseSpot. “Patients need to do their homework – a quick online search for these programs can yield significant savings. Patients also need to speak with providers about pharmacy pricing and dispensing options – providers can access these details, but most don’t share it proactively – you need to ask.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: GLP-1

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |